Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/14566
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChan, V.en
dc.contributor.authorMorris, R.en
dc.contributor.authorIlet, K.en
dc.contributor.authorTett, S.en
dc.date.issued2001en
dc.identifier.citationTherapeutic Drug Monitoring, 2001; 23(6):630-635en
dc.identifier.issn0163-4356en
dc.identifier.issn1536-3694en
dc.identifier.urihttp://hdl.handle.net/2440/14566-
dc.description.abstractThe present study estimated the population pharmacokinetics of lamotrigine in patients receiving oral lamotrigine therapy with drug concentration monitoring, and determined intersubject and intrasubject variability. A total of 129 patients were analyzed from two clinical sites. Of these, 124 patients provided sparse data (198 concentration-time points); nine patients (four from a previous group plus five from the current group) provided rich data (431 points). The population analysis was conducted using P-PHARM (SIMED Scientific Software, Cedex, France), a nonlinear mixed-effect modeling program. A single exponential elimination model (first-order absorption) with heteroscedastic weighting was used. Apparent clearance (CL/F) and volume of distribution (V/F) were the pharmacokinetic parameters estimated. Covariate analysis was performed to determine which factors explained any of the variability associated with lamotrigine clearance. Population estimates of CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.81 L/h and 78.1 +/- 5.1 L/kg. Intersubject and intrasubject variability for clearance was 38% and 38%, respectively. The covariates of concomitant valproate and phenytoin therapy accounted for 42% of the intersubject variability of clearance. Age, gender, clinic site, and other concomitant antiepileptic drugs did not influence clearance. This study of the population pharmacokinetics of lamotrigine in patients using the drug clinically provides useful data and should lead to better dosage individualization for lamotrigine.en
dc.language.isoenen
dc.publisherLippincott Williams & Wilkinsen
dc.subjectHumans; Valproic Acid; Triazines; Anticonvulsants; Metabolic Clearance Rate; Drug Interactions; Adolescent; Adult; Aged; Middle Aged; Female; Male; Lamotrigineen
dc.titlePopulation pharmacokinetics of lamotrigineen
dc.typeJournal articleen
dc.identifier.doi10.1097/00007691-200112000-00006en
pubs.publication-statusPublisheden
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.